Search
Dexamethasone Treatment Options
A collection of 1456 research studies where Dexamethasone is the interventional treatment. These studies are located in the United States. Dexamethasone is used for conditions such as Multiple Myeloma, Lymphoma and Postoperative Pain.
361 - 372 of 1456
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
Recruiting
This research is testing whether the investigational drug isatuximab is safe and effective when used in combination with standard agents for the treatment of newly diagnosed multiple myeloma.
Gender:
ALL
Ages:
75 years and above
Trial Updated:
11/08/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant
Steroids and Pain Control After Tonsillectomy
Recruiting
This research study aims to find out if a single oral dose of steroid after tonsillectomy will reduce pain and decrease the need for narcotic medications.
Gender:
ALL
Ages:
Between 3 years and 12 years
Trial Updated:
11/07/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Tonsillitis, Obstructive Sleep Apnea of Child
A Safety Study of SEA-BCMA in Patients With Multiple Myeloma
Terminated
This trial will study SEA-BCMA to find out whether it is an effective treatment for multiple myeloma (MM) and what side effects (unwanted effects) may occur.
The study will have several parts. In Parts A and B, participants get SEA-BCMA by itself. This part of the study will find out how much SEA-BCMA should be given for treatment and how often. It will also find out how safe the treatment is and how well it works.
In Part C of the study, participants will get SEA-BCMA and dexamethasone. In Pa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2024
Locations: Stanford University School of Medicine, Palo Alto, California +12 locations
Conditions: Multiple Myeloma
Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet
Completed
A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
11/01/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +45 locations
Conditions: Relapsed or Refractory Multiple Myeloma
Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma
Completed
This phase I trial studies the side effects and best dose of venetoclax when given together with ixazomib citrate and dexamethasone and to see how well they work in treating patients with multiple myeloma that has come back. Venetoclax and ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/31/2024
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan +2 locations
Conditions: Recurrent Plasma Cell Myeloma, t(11;14)
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
Active Not Recruiting
Primary Objectives:
* Safety run-in Part: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM)
* Randomized Phase 3 Part: To demonstrate the clinical benefit of isatuximab in combination with lenalidomide and dexamethasone in the prolongation of progression-free survival when compared to lenalidomide and dexamethasone in subjects with high-risk SMM
Secondary Objectives:
Safety run-in Pa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2024
Locations: UCLA Site Number : 8400010, Los Angeles, California +104 locations
Conditions: Plasma Cell Myeloma
Intravenous and Perineural Dexamethasone for Brachial Plexus Block in Hand Surgery
Completed
This study aims to evaluate the if the administration of dexamethasone both around the nerve and in the vein (perineural and intravenous (IV)) will prolong the duration of pain relief from ropivacaine when compared with ropivacaine local block alone or when administered along with IV dexamethasone in patients undergoing hand surgery.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/30/2024
Locations: The Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Hand Surgery
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
Active Not Recruiting
In this study, adults with newly-diagnosed Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) will receive first-line therapy of ponatinib or imatinib.
The main aim of this study is to compare the number of participants on each treatment that show no signs of disease.
Participants will take tablets of either ponatinib or imatinib at the same time each day combined with reduced-intensity chemotherapy for up to 20 months. Then, they will continue with single-agent therapy (p... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +91 locations
Conditions: Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
Active Not Recruiting
This phase III trial studies tretinoin and arsenic trioxide in treating patients with newly diagnosed acute promyelocytic leukemia. Standard treatment for acute promyelocytic leukemia involves high doses of a common class of chemotherapy drugs called anthracyclines, which are known to cause long-term side effects, especially to the heart. Tretinoin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Arsenic trioxide may stop the growth of cancer cells by e... Read More
Gender:
ALL
Ages:
Between 12 months and 21 years
Trial Updated:
10/28/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama +173 locations
Conditions: Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
Recruiting
This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regimens and been treated with an immunomodulatory imide drug (IMiD), proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody (mAb).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: The University of Arizona Cancer Center, Tucson, Arizona +93 locations
Conditions: Multiple Myeloma
Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma
Terminated
This is a multicenter, open-label, phase I/II clinical study, to assess the safety, tolerability, antitumor activity, pharmacokinetics and pharmacodynamics of EOS884448 (also known as EOS-448 or GSK4428859A), alone or in combination with iberdomide with and without dexamethasone in participants with relapsed/refractory multiple myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2024
Locations: Banner MD Anderson, Gilbert, Arizona +12 locations
Conditions: Multiple Myeloma
A Phase 2, Open Label, Pharmacokinetic (PK) Study of TLC599 in Subjects With Osteoarthritis of the Knee
Completed
This study is a multi-center, Phase 2, open-label, 1-period, parallel study with 9 cohorts of subjects with osteoarthritis (OA) of the knee enrolled to receive single-dose of TLC599 or Dexamethasone sodium phosphate (DSP) via IA injection and 1 cohort of healthy subjects to receive single-dose of DSP via intravenous (IV) injection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/22/2024
Locations: Arizona Research Center, Phoenix, Arizona +9 locations
Conditions: OSTEOARTHRITIS OF THE KNEE
361 - 372 of 1456